Valuation: COMPASS Pathways plc

Market Cap 1.49B 1.32B 1.23B 1.12B 2.11B 141B 2.14B 14.74B 5.78B 73.73B 5.59B 5.47B 235B P/E 2026 *
-5x
P/E 2027 * -6.42x
Enterprise Value 1.13B 1B 931M 847M 1.6B 107B 1.62B 11.19B 4.39B 55.95B 4.24B 4.15B 178B EV / Sales 2026 *
-
EV / Sales 2027 * 26.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-7.49%
1 week-10.42%
Current month-13.59%
1 month-28.33%
3 months-12.96%
6 months+61.41%
Current year+55.80%
1 week 10.72
Extreme 10.72
12.05
1 month 10.72
Extreme 10.72
15.55
Current year 4.88
Extreme 4.88
15.87
1 year 4.88
Extreme 4.88
15.87
3 years 2.25
Extreme 2.25
15.87
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 2022-07-31
Director of Finance/CFO 54 2024-02-29
Chief Tech/Sci/R&D Officer 66 2024-04-30
Director TitleAgeSince
Chairman 74 2024-03-28
Director/Board Member 69 2020-03-31
Director/Board Member 67 2021-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Tax

Chief Executive Officer

-5,962 0.0062%
5/27/26 Free

Director

21,110 0.0220%
5/27/26 Free

Director

21,110 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
-7.49%-10.42%+64.88%+72.28% 1.49B
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -2.24%-0.18%+47.46%+92.11% 37.39B
Weighted average by Cap. -2.22%-0.49%+44.33%+96.44%

Financials

2026 *2027 *
Net sales - 39.7M 35.29M 32.71M 29.76M 56.15M 3.77B 57.05M 393M 154M 1.97B 149M 146M 6.27B
Net income -299M -265M -246M -224M -422M -28.34B -429M -2.96B -1.16B -14.79B -1.12B -1.1B -47.14B -252M -224M -208M -189M -356M -23.91B -362M -2.49B -978M -12.48B -945M -925M -39.77B
Net Debt -359M -319M -296M -269M -508M -34.07B -516M -3.56B -1.39B -17.78B -1.35B -1.32B -56.68B -432M -384M -356M -324M -611M -41.01B -621M -4.28B -1.68B -21.4B -1.62B -1.59B -68.23B
Projected Income Statement - Annual - COMPASS Pathways plc
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
26-10-16 US$10.75 -7.49% 4,968,226
26-10-15 US$11.62 +3.11% 2,806,315
26-10-14 US$11.27 +1.17% 2,536,082
26-10-13 US$11.14 -3.38% 1,875,023
26-10-12 US$11.53 -3.92% 1,960,410
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - COMPASS Pathways plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
10.75USD
Average target price
23.75USD
Spread / Average Target
+120.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - COMPASS Pathways plc
  1. Stock Market
  2. Stocks
  3. CMPS Stock